Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

Gesamtdokumentation anzeigen

Y0001444

Bicalutamid

European Pharmacopoeia (EP) Reference Standard

Synonym(e):

Bicalutamid (CDX)

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C18H14F4N2O4S
CAS-Nummer:
90357-06-5
Molekulargewicht:
430.37
MDL-Nummer:
MFCD00869971
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329831426
NACRES:
NA.24
Preise und Verfügbarkeit sind derzeit nicht verfügbar.

Qualität

pharmaceutical primary standard

API-Familie

bicalutamide

Hersteller/Markenname

EDQM

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

Lagertemp.

2-8°C

SMILES String

CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc2ccc(C#N)c(c2)C(F)(F)F

InChI

1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)

InChIKey

LKJPYSCBVHEWIU-UHFFFAOYSA-N

Angaben zum Gen

human ... AR(367)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

Bicalutamide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem./physiol. Wirkung

Bicalutamide (CDX) is a non-steriodal Androgen Receptor (AR) Antagonist and a pure antiandrogen.
Bicalutamide (CDX) is a non-steriodal Androgen Receptor (AR) antagonist and a pure antiandrogen. It acts via balancing histone acetylation/deacetylation and recruitment of coregulators. Bicalutamide (CDX) abolishes androgen-mediated expression. For example, MMP13 upregulation in prostate cancer, PLZF (promyelocytic leukemia zinc finger protein), and GADD45γ (growth arrest and DNA damage inducible, gamma). Bicalutamide (CDX) is inhibited by non-genomic, transcription-independent stimulation of PI3K/AKT phosphorylation by androgens.

Verpackung

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Sonstige Hinweise

Sales restrictions may apply.

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

Y0001448

Bicalutamid für die Systemeignung, European Pharmacopoeia (EP) Reference Standard

PHR1678

Bicalutamid, Pharmaceutical Secondary Standard; Certified Reference Material

1071202

Bicalutamid, United States Pharmacopeia (USP) Reference Standard

1071213

Bicalutamid-verwandte Verbindung A, United States Pharmacopeia (USP) Reference Standard

1071224

Bicalutamid-verwandte Verbindung B, United States Pharmacopeia (USP) Reference Standard

BP1115

Bicalutamid, British Pharmacopoeia (BP) Reference Standard

BP1116

Bicalutamid-Unreinheit D, British Pharmacopoeia (BP) Reference Standard

Piktogramme

Health hazardEnvironment
GHS08,GHS09

Signalwort

Danger

Gefahreneinstufungen

Aquatic Chronic 1 - Carc. 2 - Repr. 1B

Lagerklassenschlüssel

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumente section.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Brian D Lehmann et al.
Breast cancer research : BCR, 16(4), 406-406 (2014-08-12)
Triple negative breast cancer (TNBC) is a heterogeneous collection of biologically diverse cancers, which contributes to variable clinical outcomes. Previously, we identified a TNBC subtype that has a luminal phenotype and expresses the androgen receptor (AR+). TNBC cells derived from
Wiebke Hessenkemper et al.
Molecular endocrinology (Baltimore, Md.), 28(11), 1831-1840 (2014-09-10)
We have previously identified a natural occurring, androgen receptor-specific antagonist. Atraric acid (AA) inhibits the transactivation of the androgen receptor (AR) and androgen-mediated growth of AR-expressing human prostate cancer (PCa) cell lines. Here we show that AA treatment of living
Andrew C Haller et al.
The Prostate, 74(5), 509-519 (2014-01-01)
Due to the indolent nature of prostate cancer, new prognostic measures are needed to identify patients with life threatening disease. SAM pointed domain-containing Ets transcription factor (SPDEF) has been associated with good prognosis and demonstrates an intimate relationship with the
Min Shen et al.
Journal of cellular physiology, 229(6), 688-695 (2013-10-17)
AMP-activated protein kinase (AMPK) has recently emerged as a potential target for cancer therapy due to the observation that activation of AMPK inhibits tumor cell growth. It is well-known that androgen receptor (AR) signaling is a major driver for the
G J Kolvenbag et al.
The Prostate, 34(1), 61-72 (1998-01-15)
Bicalutamide (Casodex) is a new nonsteroidal antiandrogen developed for use in patients with prostate cancer. The efficacy and tolerability of bicalutamide as monotherapy and as combination therapy for patients with advanced prostate cancer have been evaluated in randomized clinical trials.
Alle zugehörigen Dokumente anzeigen

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.